Khalid Shah, MS, PhD, Professor Harvard Medical School. Vice Chairman Neurosurgery, Director Center for Stem Cell and Translational Immunotherapy
Dr. Shah is the Vice Chair of Research at BWH Neurosurgery and Professor at Harvard Medical School. He directs of the Center for Stem Cell & Translational Immunotherapy at BWH and the joint Center of Excellence in Biomedicine with KACST and BWH. He is also a Principal Faculty at Harvard Stem Cell Institute in Boston. Dr. Shah and his team have pioneered major developments in translational cell therapy field, successfully developing gene edited and engineered cellular therapies for cancer.
Previously, Dr. Shah’s translational work has caught the attention in the public domain and was highlighted in the media world-wide including features on BBC and CNN. Recently, Dr. Shah’s laboratory has repurposed cancer cells by reverse engineering and utilized them as therapeutics to treat cancer, which was highlighted world-wide including features on Scientific American, New York Times, Boston Herald and Sky News. Amongst Dr. Shah’s published works are also two books featuring groundbreaking insights into treating cancer using different engineered cell types. He has presented his findings in more than 300 seminars worldwide and in recent years has given various keynote lectures on Innovation and Clinical Translation of biological therapies.
The potential of developing novel cancer therapies by Dr. Shah and his team has been recognized by many cancer alliances and associations and has received the young investigator, mentorship, distinguished research, innovation, idea, and impact awards for his work. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of Cell therapy and Oncology and has participated in the training of numerous undergraduate, graduate students and residents who have come from across the US and from more than 45 foreign countries.
Dr. Shah currently holds numerous patents, and he has founded two biotech companies whose main objective is the clinical translation of therapeutic cells in cancer patients. A prolific innovator, published researcher and author, Dr. Shah is passionate to harness “out of the box” therapies and ultimately find a cure for cancer.
Cell Phone Number: 1-617-899-8223
Please find more information at:
Cell-Based Immunotherapy – Center for Stem Cell and Translational Immunotherapy (CSTI) (harvard.edu)
Cancer-killing stem cells engineered in lab – BBC News
Treating cancer with re-purposed cancer cells | Khalid Shah | TEDxBoston – YouTube